Day 56 is an early time-point, and the Company is hopeful for positive trends at Day 56, but the data at the 6-month time point will provide further insights to the DMOAD capabilities of the drug along with imaging data (MRI) and clinical effect data (pain and function).
With Day 56 being an early time-point, what this means is the biomarker data at Day 56 is less relevant to the DMOAD prospects than the data at 6-months, which will "provide further insights" by showing links between Biomarker data + MRI + pain and function. So even if the biomarker data is positive, it's important to temper your expectations and not think this equates to DMOAD activity.
Day 56 data from the PARA_OA_008 trial is currently being analysed by an independent clinical research organisation to then be prepared for market release.
This means PAR do not know the results yet.
- Forums
- ASX - By Stock
- Ann: Successful MPSVI Safety Review and PARA OA 008 Update
Day 56 is an early time-point, and the Company is hopeful for...
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M |
Open | High | Low | Value | Volume |
23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33599 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 65498 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 20000 | 0.230 |
4 | 130009 | 0.225 |
12 | 183076 | 0.220 |
6 | 98958 | 0.215 |
9 | 260864 | 0.210 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 65498 | 1 |
0.245 | 48923 | 2 |
0.250 | 3443 | 1 |
0.260 | 58362 | 1 |
0.270 | 5000 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online